Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 299

1.

Effect of small molecules modulating androgen receptor (SARMs) in human prostate cancer models.

Tesei A, Leonetti C, Di Donato M, Gabucci E, Porru M, Varchi G, Guerrini A, Amadori D, Arienti C, Pignatta S, Paganelli G, Caraglia M, Castoria G, Zoli W.

PLoS One. 2013 May 8;8(5):e62657. doi: 10.1371/journal.pone.0062657. Print 2013.

PMID:
23667504
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.

Siddique HR, Mishra SK, Karnes RJ, Saleem M.

Clin Cancer Res. 2011 Aug 15;17(16):5379-91. doi: 10.1158/1078-0432.CCR-11-0916. Epub 2011 Jun 28.

PMID:
21712449
[PubMed - indexed for MEDLINE]
Free Article
3.

Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.

Kawata H, Arai S, Nakagawa T, Ishikura N, Nishimoto A, Yoshino H, Shiraishi T, Tachibana K, Nakamura R, Sato H.

Prostate. 2011 Sep;71(12):1344-56. doi: 10.1002/pros.21351. Epub 2011 Feb 9.

PMID:
21308717
[PubMed - indexed for MEDLINE]
4.

A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes.

Cherian MT, Wilson EM, Shapiro DJ.

J Biol Chem. 2012 Jul 6;287(28):23368-80. doi: 10.1074/jbc.M112.344671. Epub 2012 May 15.

PMID:
22589544
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.

Long BJ, Grigoryev DN, Nnane IP, Liu Y, Ling YZ, Brodie AM.

Cancer Res. 2000 Dec 1;60(23):6630-40.

PMID:
11118046
[PubMed - indexed for MEDLINE]
Free Article
6.

Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.

Fahrenholtz CD, Rick FG, Garcia MI, Zarandi M, Cai RZ, Block NL, Schally AV, Burnstein KL.

Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):1084-9. doi: 10.1073/pnas.1323102111. Epub 2014 Jan 6.

PMID:
24395797
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells.

Nakka M, Agoulnik IU, Weigel NL.

Int J Biochem Cell Biol. 2013 Apr;45(4):763-72. doi: 10.1016/j.biocel.2012.12.012. Epub 2012 Dec 25.

PMID:
23270728
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Establishment and characterization of androgen-independent human prostate cancer cell lines, LN-REC4 and LNCaP-SF, from LNCaP.

Iwasa Y, Mizokami A, Miwa S, Koshida K, Namiki M.

Int J Urol. 2007 Mar;14(3):233-9.

PMID:
17430262
[PubMed - indexed for MEDLINE]
9.

Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.

Schmidt A, Meissner RS, Gentile MA, Chisamore MJ, Opas EE, Scafonas A, Cusick TE, Gambone C, Pennypacker B, Hodor P, Perkins JJ, Bai C, Ferraro D, Bettoun DJ, Wilkinson HA, Alves SE, Flores O, Ray WJ.

J Steroid Biochem Mol Biol. 2014 Sep;143:29-39. doi: 10.1016/j.jsbmb.2014.02.005. Epub 2014 Feb 22.

PMID:
24565564
[PubMed - indexed for MEDLINE]
10.

Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.

Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N, Aoki Y.

Prostate. 2010 Apr 1;70(5):457-66. doi: 10.1002/pros.21079.

PMID:
19902465
[PubMed - indexed for MEDLINE]
11.

Nrf1 and Nrf2 transcription factors regulate androgen receptor transactivation in prostate cancer cells.

Schultz MA, Hagan SS, Datta A, Zhang Y, Freeman ML, Sikka SC, Abdel-Mageed AB, Mondal D.

PLoS One. 2014 Jan 22;9(1):e87204. doi: 10.1371/journal.pone.0087204. eCollection 2014.

PMID:
24466341
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

A new avenue toward androgen receptor pan-antagonists: C2 sterically hindered substitution of hydroxy-propanamides.

Guerrini A, Tesei A, Ferroni C, Paganelli G, Zamagni A, Carloni S, Di Donato M, Castoria G, Leonetti C, Porru M, De Cesare M, Zaffaroni N, Beretta GL, Del Rio A, Varchi G.

J Med Chem. 2014 Sep 11;57(17):7263-79. doi: 10.1021/jm5005122. Epub 2014 Aug 28.

PMID:
25121586
[PubMed - indexed for MEDLINE]
13.

Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.

Thomas C, Lamoureux F, Crafter C, Davies BR, Beraldi E, Fazli L, Kim S, Thaper D, Gleave ME, Zoubeidi A.

Mol Cancer Ther. 2013 Nov;12(11):2342-55. doi: 10.1158/1535-7163.MCT-13-0032. Epub 2013 Aug 21.

PMID:
23966621
[PubMed - indexed for MEDLINE]
Free Article
14.

Piperazine-designed alpha 1A/alpha 1D-adrenoceptor blocker KMUP-1 and doxazosin provide down-regulation of androgen receptor and PSA in prostatic LNCaP cells growth and specifically in xenografts.

Liu CM, Lo YC, Tai MH, Wu BN, Wu WJ, Chou YH, Chai CY, Huang CH, Chen IJ.

Prostate. 2009 May 1;69(6):610-23. doi: 10.1002/pros.20919.

PMID:
19143029
[PubMed - indexed for MEDLINE]
15.

Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line.

Mizokami A, Gotoh A, Yamada H, Keller ET, Matsumoto T.

J Urol. 2000 Sep;164(3 Pt 1):800-5.

PMID:
10953159
[PubMed - indexed for MEDLINE]
16.

Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.

Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S.

Prostate. 2013 Sep;73(12):1291-305. doi: 10.1002/pros.22674. Epub 2013 Jun 13.

PMID:
23765603
[PubMed - indexed for MEDLINE]
17.

The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.

Zhang Y, Wang XW, Jelovac D, Nakanishi T, Yu MH, Akinmade D, Goloubeva O, Ross DD, Brodie A, Hamburger AW.

Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9890-5. Epub 2005 Jun 30.

PMID:
15994225
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.

Li L, Xie H, Liang L, Gao Y, Zhang D, Fang L, Lee SO, Luo J, Chen X, Wang X, Chang LS, Yeh S, Wang Y, He D, Chang C.

Carcinogenesis. 2013 Feb;34(2):257-67. doi: 10.1093/carcin/bgs337. Epub 2012 Oct 26.

PMID:
23104178
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Steroid derivatives as pure antagonists of the androgen receptor.

Gauthier S, Martel C, Labrie F.

J Steroid Biochem Mol Biol. 2012 Oct;132(1-2):93-104. doi: 10.1016/j.jsbmb.2012.02.006. Epub 2012 Mar 23.

PMID:
22449547
[PubMed - indexed for MEDLINE]
20.

Hydrogen sulfide represses androgen receptor transactivation by targeting at the second zinc finger module.

Zhao K, Li S, Wu L, Lai C, Yang G.

J Biol Chem. 2014 Jul 25;289(30):20824-35.

PMID:
24942741
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk